Group 1 - The company N Beixin-U (688712) was listed today, opening with a rise of 187.16%, and closing with a gain of 183.33%, with a total trading volume of 28.16 million shares and a turnover of 1.409 billion yuan, resulting in a turnover rate of 75.88% [1][2] - The company specializes in the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to provide transformative solutions for cardiovascular disease diagnosis and treatment [1] - The core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the fractional flow reserve (FFR) measurement system, which is the first domestically approved product in the gold standard FFR field [1] Group 2 - The total number of shares issued by the company is 57 million, with an online issuance of 13.68 million shares at a price of 17.52 yuan per share, resulting in a final online subscription rate of 0.03264275% [2] - The initial fundraising amount is 999 million yuan, primarily directed towards the construction of an industrial base for interventional medical devices, research and development projects, working capital supplementation, and marketing network construction [2]

Core Viewpoint - North Chip Life Technology Co., Ltd. (stock code: 688712.SH) has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 49.64 yuan, representing a 183.33% increase, and a total market capitalization of 20.7 billion yuan [1]. Company Overview - North Chip Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [1]. - The company aims to provide transformative solutions for cardiovascular disease diagnosis and treatment, covering five major product categories including IVUS and FFR systems [1]. Financial Performance - The company reported a cumulative loss of 686.41 million yuan as of June 30, 2025, indicating potential challenges in future cash dividends [2]. - From 2022 to 2024, the company experienced a total net loss of 473.40 million yuan, with revenues increasing from 92.45 million yuan in 2022 to 316.60 million yuan in 2024 [8][9]. Shareholding Structure - The company has no controlling shareholder, with the actual controller being Song Liang, who holds 16.15% of the shares directly and has significant influence over company decisions [2][3]. - Other shareholders are primarily financial investors who do not seek control of the company, supporting Song Liang's position as the actual controller [3]. Fundraising and Use of Proceeds - North Chip Life raised a total of 998.64 million yuan in its IPO, with a net amount of 898.89 million yuan after deducting issuance costs [5]. - The funds will be allocated to the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital, with a total planned investment of 952.21 million yuan [6][7]. Future Projections - For 2025, the company expects revenue between 520 million yuan and 560 million yuan, representing a growth of 64.24% to 76.88% year-over-year, and a net profit of 78 million yuan to 88 million yuan, indicating a growth of 278.91% to 301.85% [13].

Company Overview - N Beixin-U is a national high-tech enterprise focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to revolutionize solutions in this field [2][6] - The company's core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration (NMPA) in China, and the fractional flow reserve (FFR) measurement system, which is the first domestically approved product in the gold standard FFR field [2][6] Market Position - N Beixin-U is the first domestic medical device company to have a combination of intravascular functional FFR and imaging IVUS products, filling a gap in the domestic market and changing the reliance on imported products for precise diagnosis of coronary artery diseases in China [2][6] - The company has established a high-performance and high-barrier system for active interventional medical devices, continuously achieving successful research and commercialization of innovative products, gaining recognition in both domestic and international markets [2][6] IPO Details - The company went public today with an opening price of 50.31 yuan, reflecting a 187.16% increase from the issuance price of 17.52 yuan per share [3][7] - A total of 57 million shares were issued, with 13.68 million shares available for online subscription, and the final subscription rate was 0.03264275% [3][7] - The IPO raised approximately 999 million yuan, with funds allocated for the construction of an interventional medical device industrialization base, R&D projects, working capital, and marketing network development [3][7]

Group 1 - The company N北芯-U (688712) was listed today, opening with a significant increase of 187.16%, and closing the morning session with a rise of 185.67% [1][2] - The total trading volume for the half-day reached 21.47 million shares, with a transaction value of 1.082 billion yuan, resulting in a turnover rate of 57.85% [1][2] - The company specializes in the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, positioning itself as a national high-tech enterprise [1] Group 2 - The core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the fractional flow reserve (FFR) measurement system, which is the first domestic product in the FFR field approved by the same authority [1] - Both products have entered the special review process for innovative medical devices, potentially transforming clinical practices for percutaneous coronary intervention (PCI) surgeries [1] - The company is the first domestic medical device company to offer a combination of vascular functional FFR and imaging IVUS products, filling a gap in the domestic market and changing the reliance on imported products for precise diagnosis of coronary artery diseases in China [1]

核心产品血流储备分数(FFR)测量系统为金标准FFR领域内中国首个获国家药监局批准的国产产品，上述两款产品 均进入了国家创新医疗器械特别审查程序，有望为精准指导经皮冠状动脉介入治疗(PCI)手术临床实践带来变革。 公司核心产品上市后迅速占据国内市场市占率第二且国产品牌市占率第一，实现高端有源介入医疗器械国产化率的 提升。 智通财经APP获悉，1月26日，北芯生命(688712.SH)开启申购，发行价格为17.52元/股，申购上限为0.9万股，行业 市盈率41.36倍，属于上交所，中金公司为其保荐机构。 招股书显示，北芯生命是一家专注于心血管疾病精准诊疗创新医疗器械研发、生产和销售的技术企业，亦致力于开 发为心血管疾病诊疗带来变革的精准解决方案。 截至2025年9月30日，公司累计向市场推出11个产品，在研产品共有6个，覆盖IVUS系统、FFR系统、血管通路产 品、冲击波球囊治疗系统及电生理解决方案五大产品类别。 公司核心产品IVUS系统是中国首个自主创新60MHz高清高速国产IVUS产品，拥有高清、高速、智能三大特点，可 高效便捷指导精准PCI策略制定。 公司根据创新医疗器械行业特点，主要通过销售一次性使用耗 ...

Core Viewpoint - Beixin Life is planning to publicly issue 57 million shares, all of which are new shares, resulting in a total share capital of 41.7 million shares after issuance [1] Company Overview - Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to revolutionize solutions in this field [2] - The company's core products include the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, both of which are the first domestically developed products approved by the National Medical Products Administration (NMPA) in China [2][3] - Beixin Life is the first domestic medical device company to offer a combination of FFR and IVUS products, filling a gap in the domestic market and reducing reliance on imported products [2] Product Development - Since its establishment, the company has launched 11 products and has 6 products under development, covering five categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [3] - The IVUS system is recognized for its high-definition, high-speed, and intelligent features, and is included in the National Key R&D Program for digital diagnostic equipment [3] Financial Data - As of June 30, 2025, the total assets amounted to 838.54 million yuan, with a net profit of 45.51 million yuan, marking a significant improvement from previous years [8] - The company reported a revenue of 258.86 million yuan for the first half of 2025, compared to 186.98 million yuan in 2023 [8] Market Position - Beixin Life specializes in precise cardiovascular disease diagnosis solutions, competing with major companies like Boston Scientific, Abbott, Philips, and Lepu Medical in the IVUS and FFR segments [9] - The company has achieved a leading market share in the domestic market for its core products, significantly reducing the dependency on imports [9][10] - Beixin Life's innovative capabilities and management team position it well for growth in the high-end active interventional diagnosis and treatment market, where domestic competitors have yet to make significant breakthroughs [10]

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has officially initiated its A-share listing process on the Shanghai Stock Exchange's Sci-Tech Innovation Board, aiming to raise approximately 9.52 billion yuan through the issuance of 57 million shares, which will account for 13.67% of the total share capital post-issuance [1] Group 1: Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - The company has developed the first domestically produced 60MHz high-definition IVUS product and the first domestically approved FFR measurement system in China [1] Group 2: Product Development and Market Position - As of September 30, 2025, Beixin Life has launched 11 products and has 6 products under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [2] - The FFR system captured a 30.6% market share in China shortly after its launch in 2020, with over 70% of its domestic usage coming from tertiary hospitals [2] Group 3: Financial Performance and Projections - Beixin Life's revenue is projected to grow significantly, with expected revenues of 520 million to 560 million yuan in 2025, representing a year-on-year growth of 64.24% to 76.88% [3] - The company anticipates a substantial increase in net profit, with estimates ranging from 78 million to 88 million yuan, reflecting a year-on-year growth of 278.91% to 301.85% [3] Group 4: Strategic Initiatives and Future Outlook - The funds raised from the IPO will be primarily allocated to the construction of an industrialization base for interventional medical devices, R&D projects, and to supplement working capital [3] - The company aims to enhance its capital structure, reduce debt risk, and improve its resilience against market fluctuations, while also expanding production capacity and strengthening R&D capabilities [3]

Group 1 - The company, Beixin Life (688712.SH), plans to publicly issue 57 million shares, accounting for 13.67% of the total share capital after the issuance [1] - The initial strategic placement will involve 11.4 million shares, representing 20% of the total issuance, with senior management and core employees participating in a special asset management plan for 5.7 million shares, which is 10% of the total issuance [1] - The initial strategic placement by the sponsoring institution, China International Capital Corporation Wealth Securities Co., Ltd., is expected to be 2.85 million shares, or 5% of the total issuance, with a subscription amount not exceeding 40 million yuan [1] Group 2 - The company specializes in innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, recognized as a national high-tech enterprise [2] - The core products include the intravascular ultrasound (IVUS) diagnostic system, the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the flow reserve fraction (FFR) measurement system, the first domestic product in the FFR field approved by the same authority [2] - The company reported net profits attributable to the parent company of -290 million yuan, -140 million yuan, -43.596 million yuan, and 49.4496 million yuan for the years 2022 to the first half of 2025, with an expected profit of 78 million to 88 million yuan for 2025, representing a growth of 278.91% to 301.85% compared to the previous year [2] - The total planned investment of 952 million yuan from the fundraising will be allocated to the construction of an interventional medical device industrialization base, research and development projects, and to supplement working capital [2]

Group 1 - The company, Beixin Life (688712.SH), plans to publicly issue 57 million shares, accounting for 13.67% of the total share capital after the issuance [1] - The initial strategic placement will involve 11.4 million shares, representing 20% of the total issuance, with senior management and core employees participating in a special asset management plan for 5.7 million shares, which is 10% of the total issuance [1] - The initial strategic placement by the sponsoring institution, China International Capital Corporation Wealth Securities Co., Ltd., is expected to be 2.85 million shares, or 5% of the total issuance, with a subscription amount not exceeding 40 million yuan [1] Group 2 - The company focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, being a national high-tech enterprise [2] - Its core products include the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, both of which are the first domestically approved products in China [2] - The company reported net profits attributable to the parent company of -290 million yuan, -140 million yuan, -43.596 million yuan, and 49.4496 million yuan for the years 2022 to the first half of 2025, with an expected profit of 78 million to 88 million yuan for 2025, representing a growth of 278.91% to 301.85% year-on-year [2] - The total planned investment from the raised funds, after deducting issuance costs, is 952 million yuan, allocated to the construction of an interventional medical device industrialization base, R&D projects, and working capital [2]

Core Viewpoint - The successful IPO of Shenzhen Beixin Life Technology Co., Ltd. marks the second company to pass the review under the newly restarted fifth set of standards for the Sci-Tech Innovation Board [1] Company Overview - Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to revolutionize solutions in this field [3] - The company is recognized as a national high-tech enterprise and has developed China's first domestically innovative 60MHz high-definition IVUS product approved by the National Medical Products Administration [3][4] - Beixin Life is the first domestic medical device company to offer a combination of FFR and IVUS products, addressing the previously import-dependent market for coronary artery disease diagnosis in China [3][4] Product Development - Since its establishment, Beixin Life has launched 11 products and has 6 products under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [4][5] - The core IVUS system is noted for its high-definition, high-speed, and intelligent features, which facilitate precise PCI strategy formulation [4] - The FFR system is recognized as the gold standard for PCI treatment guidance and has received high-level recommendations from various domestic and international guidelines [4] Financial Performance - From 2022 to 2024, Beixin Life's projected revenues are 92.45 million yuan, 184 million yuan, and 317 million yuan, with net profits of -179 million yuan, -164 million yuan, and -6.29 million yuan respectively [5] - The company plans to raise 952 million yuan through its IPO to fund the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital [5] - Cumulatively, the company has invested over 389 million yuan in R&D from 2022 to 2024, accounting for over 65% of its total revenue during this period [5]